BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yndestad A, Vinge LE, Bjørnerheim R, Ueland T, Wang JE, Frøland SS, Attramadal H, Aukrust P, Øie E. Thalidomide attenuates the development of fibrosis during post-infarction myocardial remodelling in rats. European Journal of Heart Failure 2006;8:790-6. [DOI: 10.1016/j.ejheart.2006.02.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Järveläinen H, Sainio A, Koulu M, Wight TN, Penttinen R. Extracellular Matrix Molecules: Potential Targets in Pharmacotherapy. Pharmacol Rev 2009;61:198-223. [DOI: 10.1124/pr.109.001289] [Reference Citation Analysis]
2 Scharpfenecker M, Floot B, Russell NS, Coppes RP, Stewart FA. Thalidomide Ameliorates Inflammation and Vascular Injury but Aggravates Tubular Damage in the Irradiated Mouse Kidney. International Journal of Radiation Oncology*Biology*Physics 2014;89:599-606. [DOI: 10.1016/j.ijrobp.2014.03.039] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
3 Hoving S, Seemann I, Visser NL, Te Poele JA, Stewart FA. Thalidomide is not able to inhibit radiation-induced heart disease. International Journal of Radiation Biology 2013;89:685-91. [DOI: 10.3109/09553002.2013.788797] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
4 Bonsu KO, Owusu IK, Buabeng KO, Reidpath DD, Kadirvelu A. Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies. Ther Clin Risk Manag 2016;12:887-906. [PMID: 27350750 DOI: 10.2147/TCRM.S106065] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
5 Kim DH, Kim YJ, Chang SA, Lee HW, Kim HN, Kim HK, Chang HJ, Sohn DW, Park YB. The protective effect of thalidomide on left ventricular function in a rat model of diabetic cardiomyopathy. Eur J Heart Fail 2010;12:1051-60. [PMID: 20601373 DOI: 10.1093/eurjhf/hfq103] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
6 Patel C, Deoghare S. Heart failure: novel therapeutic approaches. J Postgrad Med 2015;61:101-8. [PMID: 25766342 DOI: 10.4103/0022-3859.153104] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
7 Zhang H, Yang Y, Wang Y, Wang B, Li R. Renal-protective effect of thalidomide in streptozotocin-induced diabetic rats through anti-inflammatory pathway. Drug Des Devel Ther 2018;12:89-98. [PMID: 29386886 DOI: 10.2147/DDDT.S149298] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
8 Arai H, Furusu A, Nishino T, Obata Y, Nakazawa Y, Nakazawa M, Hirose M, Abe K, Koji T, Kohno S. Thalidomide prevents the progression of peritoneal fibrosis in mice. Acta Histochem Cytochem 2011;44:51-60. [PMID: 21614166 DOI: 10.1267/ahc.10030] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
9 Järveläinen H, Sainio A, Koulu M, Wight TN, Penttinen R. Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacol Rev 2009;61:198-223. [PMID: 19549927 DOI: 10.1124/pr.109.001289] [Cited by in Crossref: 286] [Cited by in F6Publishing: 266] [Article Influence: 23.8] [Reference Citation Analysis]
10 Choe JY, Jung HJ, Park KY, Kum YS, Song GG, Hyun DS, Park SH, Kim SK. Anti-fibrotic effect of thalidomide through inhibiting TGF-beta-induced ERK1/2 pathways in bleomycin-induced lung fibrosis in mice. Inflamm Res 2010;59:177-88. [PMID: 19757088 DOI: 10.1007/s00011-009-0084-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]